(secondQuint)MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone.

 This is a multicenter, randomized, rater- and dose-blinded, study to compare the efficacy and safety of 0.

25 mg and 0.

5 mg of fingolimod with glatimer acetate 20 mg s.

c.

 in patients with RRMS.

 This study will consist of 3 periods: - Screening Period: up to 1 month for all patients - Treatment Period: 12 months of glatiramer acetate 20 mg, fingolimod 0.

25 mg, or fingolimod 0.

5 mg - Follow-up will occur 3 months (12 weeks) after the last dose of study drug for all patients After signing the informed consent, patients will enter the Screening Period to determine eligibility for the study.

 After inclusion/exclusion criteria are reviewed again and after safety assessments are conducted, patients will enter the Treatment Period and will be randomly assigned into 1 of 3 groups in a 1:1:1 ratio: - Group 1 will receive fingolimod 0.

5 mg orally once a day for up to 12 months - Group 2 will receive fingolimod 0.

25 mg orally once a day for up to 12 months - Group 3 will receive glatiramer acetate 20 mg subcutaneously once a day for up to 12 months.

 MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone@highlight

The purpose of this study is to compare 2 doses (0.

25 mg and 0.

50 mg) of fingolimod to glatiramer acetate (20 mg) and to evaluate the efficacy of fingolimod 0.

25 mg for the treatment of patients with relapsing-remitting MS (RRMS).

